Advertisement

Topics

Targovax Announces Encouraging Results From Part 1 of the ONCOS-102 and Keytruda Combination Trial in Anti-PD1 Refractory Melanoma

12:52 EDT 8 Jul 2019 | FinanzNachrichten

- One complete response (CR) and two partial responses (PR) observed for the nine patients in part 1 (33% ORR), who received only three ONCOS-102 injections - Innate and adaptive immune activation...

Original Article: Targovax Announces Encouraging Results From Part 1 of the ONCOS-102 and Keytruda Combination Trial in Anti-PD1 Refractory Melanoma

NEXT ARTICLE

More From BioPortfolio on "Targovax Announces Encouraging Results From Part 1 of the ONCOS-102 and Keytruda Combination Trial in Anti-PD1 Refractory Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement